Legal & General Group
SCPS

Legal & General Group’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Legal & General Group’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-541
Closed -$5K – 3720
2021
Q1 		$5K Buy
+541
New +$5.66K ﹤0.01% 3491

Other funds holding SCPS

BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group's SCPS Position: Q2 2021 in Review

Legal & General Group sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q2 2021, closing a stake of 541 shares — an estimated $5K sold.

Legal & General Group first reported a position in SCPS in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 15 funds tracked by Wall St. Rank hold SCPS as of Q2 2021.

  • Legal & General Group reported no remaining Scopus BioPharma Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 541 Scopus BioPharma Inc. Common Stock shares in Q2 2021, an estimated $5K.
  • Legal & General Group first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Legal & General Group's Scopus BioPharma Inc. Common Stock position peaked at $5K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.